Trial Profile

Efficacy and Safety of X-396(Ensartinib) in ALK-Positive NSCLC Patients With Brain Metastases: A Phase II, Open-Label, Single Arm, Multicenter Study

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ensartinib (Primary)
Indications Brain metastases; Non-small cell lung cancer
Focus Therapeutic Use

Most Recent Events

23 Jul 2025 Planned End Date changed from 1 Oct 2020 to 30 Jun 2026.
23 Jul 2025 Status changed from recruiting to active, no longer recruiting.
24 Oct 2023 Results (n=17; as of 24 Mar 2023) presented at the 48th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com